Mimedx (MDXG) Change in Receivables (2011 - 2026)
Mimedx (MDXG) posted Change in Receivables of $545000.0 for Q2 2026, up 101.93% sequentially from -$28.2 million in Q1 2026, and down 92.52% YoY from $7.3 million in Q2 2025.
Mimedx (MDXG) Change in Receivables (2011 - 2026) Analysis & Trends
Mimedx has reported Change in Receivables for 15 years, with the latest figure at $545000.0 in Q2 2026.
- Quarterly Change in Receivables fell 92.52% year-over-year to $545000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$15.8 million (down 189.06% YoY) and the FY2025 annual result came in at $26.4 million, up 934.25% from the prior year.
- Change in Receivables climbed to $545000.0 in Q2 2026 per MDXG's latest filing, from -$28.2 million in the prior quarter.
- Over five years, Change in Receivables peaked at $11.0 million in Q3 2025 and troughed at -$28.2 million in Q1 2026.
- A 5-year average of $1.1 million and a median of $2.3 million in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables slumped 89200.0% in 2022, then soared 1055.72% in 2025.
- Over 5 years, Change in Receivables stood at $2.6 million in 2022, then jumped by 111.13% to $5.6 million in 2023, then tumbled by 59.61% to $2.3 million in 2024, then sank by 60.63% to $887000.0 in 2025, then sank by 38.56% to $545000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $545000.0, -$28.2 million, and $887000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 545,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 545,000.00 |
| Jun 30, 2026 | 545,000.00 |
| Mar 31, 2026 | -28.21 Mn |
| Mar 31, 2026 | -28.21 Mn |
| Dec 31, 2025 | 887,000.00 |
| Dec 31, 2025 | 887,000.00 |
| Sep 30, 2025 | 11.01 Mn |
| Sep 30, 2025 | 11.01 Mn |
| Jun 30, 2025 | 7.29 Mn |
| Jun 30, 2025 | 7.29 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Sep 30, 2024 | 953,000.00 |
| Sep 30, 2024 | 953,000.00 |
| Jun 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -4.00 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Mar 31, 2024 | 3.34 Mn |